Want to see NMTC full AI Analyst Report?
NMTC Stock Chart & Stats
$1.90
-$0.15(-7.89%)
At close: 4:00 PM EDT
$1.90
-$0.15(-7.89%)
Day’s Range― - ―
52-Week Range$1.61 - $6.96
Previous CloseN/A
Volume16.98K
Average Volume (3M)532.45K
Market Cap
$14.53M
Enterprise Value$36.93
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$206.97K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 19, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding8,702,982
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.67Price Target Upside408.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.28
Revenue Forecast (FY)$10.68M
Bulls Say, Bears Say
Bulls Say
Product Revenue TractionSustained product revenue growth shows improving commercial adoption of the OneRF platform and expanding procedure usage. Durable unit demand growth (72% YoY in Q2; TTM up ~11.5%) supports scaling revenue, operating leverage over time, and validates product-market fit versus early-stage comparables.
Healthy Product Gross MarginsProduct-level gross margins in the mid-50s indicate attractive unit economics for thin-film electrodes and OneRF procedures. These margin levels create room for profitable scaling if fixed SG&A and R&D remain disciplined, enabling margin expansion as revenue base grows and manufacturing efficiencies improve.
Established Distribution PartnershipA commercial partnership with Zimmer Biomet provides an established route to scale, regulatory and channel expertise, and faster market access internationally. This structural distribution advantage accelerates adoption and reduces NeuroOne’s need to build global sales infrastructure from scratch.
Bears Say
High Cash Burn / Tight LiquiditySustained negative operating cash flow and a steep cash decline materially compress the company’s runway absent financing. Persistent burn forces reliance on equity raises or partner-funded milestones, increasing dilution risk and constraining ability to invest consistently in commercial expansion or clinical programs.
Persistent Large Net LossesDeep, persistent negative margins and very poor ROE show the business is not yet converting growth into profitability. Sustained losses limit internal funding for R&D and commercialization, increase capital needs, and heighten execution risk until unit scale and operating leverage materially improve.
Dependence On Partners And Timing UncertaintyKey growth pathways rely on partners’ execution and timing (Zimmer Biomet, distributors, and collaborators). This reduces NeuroOne’s visibility into procedure-level demand and creates execution risk: delays or limited partner prioritization can materially push out international scale and revenue realization.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $1.61 and its highest was $6.96 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $14.53M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is Aug 19, 2026 which is in 20 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on May 12, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.227 by -$0.023.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.58.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 8,702,982 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.227. Following the earnings report the stock price went up 1.386%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
NMTC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and clinical progress — notably 72% Q2 product revenue growth, publication and clinical wins, ISO audit progress, regained NASDAQ compliance, and no debt — alongside strategic hires and partnership momentum. However, material financial and timing challenges temper the optimism: cash balances declined sharply (~57.6%), there was no license revenue this year (vs. $3.0M prior), six-month net loss widened to $3.5M, and gross margins compressed. Several growth catalysts (international rollout, drug delivery commercial availability, spinal cord stimulation timeline) remain contingent on future milestones or partner actions and thus introduce execution and timing risk. Balancing the clear operational wins against the pronounced near-term liquidity and revenue-recognition headwinds yields a neutral overall view.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$9.67
▲(408.77% Upside)
Technical Analysis
Ownership Overview
31.85% Insiders
2.81% Other Institutional Investors
61.10% Public Companies and
Individual Investors